xFurther details from the phase 2b AZALEA trial with the factor XI inhibitor abelacimab (Anthos) show significant reductions in major and clinically relevant nonmajor bleeding compared with rivaroxaban for patients with AF; the risk of stroke was moderate to high. The trial was stopped earlier this year because of an “overwhelming” reduction in bleeding with …
The widely available blood thinner apixaban substantially reduced stroke in at-risk patients with a type of atrial fibrillation only detectable by a pacemaker or other implanted cardiac electronic device, a global study has found. The oral anticoagulant medication, which helps to prevent dangerous blood clots by thinning the blood, reduced the risk of stroke and …
In patients with subclinical atrial fibrillation (AF) detected by implanted devices such as pacemakers or loop recorders, oral anticoagulation with apixaban resulted in a lower risk of stroke or systemic embolism than aspirin, but a higher risk of major bleeding in the ARTESIA study. The results appear to contrast somewhat with the recently reported NOAH-AFNET …